Grace Therapeutics, Inc.
GRCE · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $28 | $22 | $22 | $18 |
| - Cash | $22 | $23 | $28 | $30 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | -$1 | -$5 | -$12 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$17 | -$15 | -$18 | -$15 |
| % Margin | – | – | – | – |
| Net Income | -$10 | -$13 | -$42 | -$10 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.79 | -1.73 | -5.71 | -1.6 |
| % Growth | 54.3% | 69.7% | -256.9% | – |
| Operating Cash Flow | -$15 | -$12 | -$16 | -$17 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$15 | -$12 | -$16 | -$17 |